TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25975816

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 30 mg pioglitazone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 50 mg miglitol
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 1 mg glimepiride
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 250 mg metformin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 50 mg sitagliptin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 mg luseogliflozin + 0.6 mg voglibose
Number of subjects: 72
Study: 23118347

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control (drugs with inert CYP effects)
Number of subjects: 98
Study: 21733529

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 119
Study: 19665279

Group type: EXPERIMENTAL
Intervention: Gonadotrophin-releasing hormone analogue (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Continuous low-dose monophasic oral contraceptives (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Dietary therapy (vitamins, minerals salts, lactic ferments, fish oil)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 17052809

Group type: EXPERIMENTAL
Intervention: Enteral nutrition enriched with carotenoids (3-mg/1500kcal) for 3 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (enteral nutrition without carotenoids)
Number of subjects: 51
Study: 15269070

Group type: EXPERIMENTAL
Intervention: Weaning before or at 12 weeks
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Weaning after 12 weeks
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Breast fed term infants weaned before 12 weeks
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Weaning before or after 12 weeks
Number of subjects: 1600
Study: 11764123

Group type: EXPERIMENTAL
Intervention: Visible light‐cured material
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heat‐cured acrylic
Number of subjects: 10
Study: 9249859

Group type: EXPERIMENTAL
Intervention: Elevated MShCG level (cut-off level of 2.5 MOM)
Number of subjects: 10459

Group type: EXPERIMENTAL
Intervention: Elevated MSAFP level
Number of subjects: 10459

Group type: EXPERIMENTAL
Intervention: Combined elevation of MSAFP and MShCG levels
Number of subjects: 10459
Study: 7831376

Group type: EXPERIMENTAL
Intervention: HA-1A treatment
Number of subjects: 0
Study: 3078426

Group type: EXPERIMENTAL
Intervention: Nifedipine (4 mcg/Kg/L) added to cold potassium cardioplegia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (cold potassium cardioplegia without nifedipine)
Number of subjects: 24
Study: 29886771

Group type: EXPERIMENTAL
Intervention: Early removal of indwelling catheter (2 hours after cesarean section)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed removal of indwelling catheter (12 hours after cesarean section)
Number of subjects: 134
Study: 31194864

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 45976

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 45976
Study: 28821903

Group type: EXPERIMENTAL
Intervention: Recovery-focused video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom-focused video
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-video control condition
Number of subjects: 0
Study: 25876886

Group type: EXPERIMENTAL
Intervention: Microdebrider-assisted total intracapsular tonsillectomy (ICTE)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional extracapsular tonsillectomy (ECTE)
Number of subjects: 104
Study: 23452697

Group type: EXPERIMENTAL
Intervention: Forced-air warming blanket preoperatively
Number of subjects: 128

Group type: COMPARATOR
Intervention: No forced-air warming (control group)
Number of subjects: 128
Study: 21605239

Group type: EXPERIMENTAL
Intervention: Fractionated CO(2) laser with rolling handpiece
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fractionated CO(2) laser with stamping handpiece
Number of subjects: 8
Study: 19638215

Group type: EXPERIMENTAL
Intervention: intensive dietary restriction- plus- exercise
Number of subjects: 450

Group type: COMPARATOR
Intervention: exercise-only
Number of subjects: 450

Group type: COMPARATOR
Intervention: intensive dietary restriction-only
Number of subjects: 450
Study: 16775510

Group type: EXPERIMENTAL
Intervention: Red wine (RW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DARW)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Polyphenols-stripped red wine (PSRW)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ethanol-water solution (ET)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 9
Study: 15181040

Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin 0.1 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin 1.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: r‐metHuLeptin (all doses)
Number of subjects: 0
Study: 11303370

Group type: EXPERIMENTAL
Intervention: BAM (bismuth-subcitrate, amoxycillin, and metronidazole) for 7 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LCM (lansoprazole, clarithromycin, and metronidazole) for 7 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: LAC (lansoprazole, amoxycillin, and clarithromycin) regardless of culture results
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lansoprazole and two antibacterial agents chosen according to susceptibility test
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination therapy based on proton pump inhibitor and two antibiotics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gastric-mucosal culture testing for sensitivity of H. pylori to antibiotics
Number of subjects: 90
Study: 9291755

Group type: EXPERIMENTAL
Intervention: Conventional resuscitation
Number of subjects: 18
Study: 8287568

Group type: EXPERIMENTAL
Intervention: hGH treatment (group I) for 12 months
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: hGH treatment (group I)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 83
Study: 3535493

Group type: EXPERIMENTAL
Intervention: Weight control program with self-monitoring of blood glucose levels
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard behavioral weight control program
Number of subjects: 50
Study: 29464905

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) program focused on controlling GWG through nutrition and activity behaviors
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual obstetrical care (UC)
Number of subjects: 210
Study: 27018313

Group type: EXPERIMENTAL
Intervention: Conservative fluid management
Number of subjects: 625

Group type: COMPARATOR
Intervention: Liberal fluid management
Number of subjects: 625
Study: 23956183

Group type: EXPERIMENTAL
Intervention: Involuntary breath stacking (IBS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Voluntary breath stacking (VBS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Supported breath stacking (SBS)
Number of subjects: 23
Study: 22724427

Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drink (AmED)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.91 ml/kg vodka
Number of subjects: 80

Group type: COMPARATOR
Intervention: 1.82 ml/kg energy drink
Number of subjects: 80
Study: 21713704

Group type: EXPERIMENTAL
Intervention: EEN+glutamine (EEN+Gln)
Number of subjects: 80

Group type: COMPARATOR
Intervention: EEN
Number of subjects: 80
Study: 18304176

Group type: EXPERIMENTAL
Intervention: Exercise with showering within 1 hour (group 2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise with showering after 4 hours (group 3)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No exercise (group 1)
Number of subjects: 23
Study: 17002080

Group type: EXPERIMENTAL
Intervention: Short-term educational intervention on mastery goal orientation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 12742841

Group type: EXPERIMENTAL
Intervention: Classification system for visual field abnormalities
Number of subjects: 1636
Study: 10973650

Group type: EXPERIMENTAL
Intervention: Filshie Clip
Number of subjects: 2746

Group type: EXPERIMENTAL
Intervention: Tubal Ring
Number of subjects: 2746
Study: 8653101

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2067362

Group type: EXPERIMENTAL
Intervention: Protamine pretreatment (PP) 2 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 16
Study: 30683155

Group type: EXPERIMENTAL
Intervention: Multi-thematic coaching (training in patient-centred coaching, shared decision-making, and motivational interviewing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art smoking cessation algorithm (control group)
Number of subjects: 0
Study: 29030065

Group type: EXPERIMENTAL
Intervention: Diuretic treatment (40mg bolus of furosemide)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Volume expansion (500mL of saline infusion)
Number of subjects: 46
Study: 25380294

Group type: EXPERIMENTAL
Intervention: High 25OHD and high PA (VitD+PA+)
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: High 25OHD
Number of subjects: 615

Group type: COMPARATOR
Intervention: Low 25OHD
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Moderate/vigorous PA
Number of subjects: 615
Study: 23785427

Group type: EXPERIMENTAL
Intervention: Facilitated interactive workshops
Number of subjects: 108

Group type: COMPARATOR
Intervention: Access to a guideline for acute LBP
Number of subjects: 108
Study: 22770793

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA)
Number of subjects: 2183
Study: 19730244

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study: 17024628

Group type: EXPERIMENTAL
Intervention: High volume resistance training (3 sets/station)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low volume resistance training (1 set/station)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Individuals with lowest pretraining vascular measures
Number of subjects: 35
Study: 15365927

Group type: EXPERIMENTAL
Intervention: Ketorolac and opioid analgesics
Number of subjects: 70

Group type: COMPARATOR
Intervention: Opioid analgesics alone
Number of subjects: 70
Study: 11672580

Group type: COMPARATOR
Intervention: Hypotensive anesthesia (HYPO‐R: remifentanil, HYPO‐N: nitroglycerin)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Normotensive anesthesia (NORMO: propofol and remifentanil)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypotensive anesthesia (HYPO‐R and HYPO‐N)
Number of subjects: 30
Study: 9884710

Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade
Number of subjects: 120
Study: 7841753

Group type: EXPERIMENTAL
Intervention: Ligusticum wallichii Mixture (LWM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2453744

Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg, twice daily for 24 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acebutolol (480 mg, twice daily for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Acebutolol (acute and long-term treatment)
Number of subjects: 10
Study: 31473598

Group type: EXPERIMENTAL
Intervention: EBI plus general counselling
Number of subjects: 210

Group type: COMPARATOR
Intervention: General counselling alone
Number of subjects: 210
Study: 30208396

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan: Moving for Better Balance (TJQMBB)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Multimodal Exercise (MME)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Stretching Exercise
Number of subjects: 670
Study: 26329656

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) with low dosage of fentanyl (15 μg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High dosage of fentanyl (30 μg/kg) with normal saline (control group)
Number of subjects: 50
Study: 26317510

Group type: EXPERIMENTAL
Intervention: Payment for Performance (P4P) scheme
Number of subjects: 3000
Study: 24010549

Group type: EXPERIMENTAL
Intervention: Moderate red wine intake (250 mL/day for 4 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no red wine intake)
Number of subjects: 41
Study: 21536465

Group type: EXPERIMENTAL
Intervention: Hyperpolarized helium-3 (HHe) ventilation MRI
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Hyperpolarized helium-3 (HHe) ADC MRI
Number of subjects: 1
Study: 18561360

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-preferred hand in advanced stages
Number of subjects: 0
Study: 16814635

Group type: EXPERIMENTAL
Intervention: HF-delivered reattribution training
Number of subjects: 70

Group type: COMPARATOR
Intervention: No reattribution training
Number of subjects: 70
Study: 14673053

Group type: EXPERIMENTAL
Intervention: 20 mg of oral paroxetine hydrochloride daily
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study: 11184958

Group type: EXPERIMENTAL
Intervention: Short questionnaire (4 pages)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Medium questionnaire (5 pages)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Long questionnaire (7 pages)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: All questionnaires
Number of subjects: 847
Study: 8818199

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (16g leucine, 2g isoleucine, 2g valine per day)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 17
Study: 1424424

Group type: EXPERIMENTAL
Intervention: Nicorandil (10 to 60 mg)
Number of subjects: 25
Study: 6731879

Group type: EXPERIMENTAL
Intervention: 4 mg/kg of cimetidine only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg of metoclopramide only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 4 mg/kg of cimetidine and 0.15 mg/kg of metoclopramide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline only
Number of subjects: 60
Study: 31087542

Group type: EXPERIMENTAL
Intervention: TCZ‐SC 162 mg qw
Number of subjects: 401

Group type: COMPARATOR
Intervention: TCZ‐SC 162 mg q2w
Number of subjects: 401
Study: 28693515

Group type: EXPERIMENTAL
Intervention: 30‐h communication skills training (CST) program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 60
Study: 26686682

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil (AZL-M)
Number of subjects: 3698

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 3698

Group type: COMPARATOR
Intervention: Azilsartan medoxomil (AZL-M) and Ramipril
Number of subjects: 3698
Study: 24317556

Group type: EXPERIMENTAL
Intervention: D-fortified group (n = 55)
Number of subjects: 55

Group type: COMPARATOR
Intervention: D-placebo group (n = 54)
Number of subjects: 55
Study: 20965941

Group type: EXPERIMENTAL
Intervention: everolimus 10 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 18602824

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (5 g, twice daily for 4 weeks)
Number of subjects: 16
Study: 16429095

Group type: EXPERIMENTAL
Intervention: Parents who responded to antidepressant therapy (defined as at least a 40% reduction in depressive symptoms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parents who did not respond to antidepressant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents who responded to treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parents who did not respond to treatment
Number of subjects: 0
Study: 12855089

Group type: EXPERIMENTAL
Intervention: Visual stimulation (V-sessions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Static blank screen (B-sessions)
Number of subjects: 33
Study: 11195715

Group type: EXPERIMENTAL
Intervention: Stage 1 sleep preceded by alpha
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage 1 sleep preceded by theta
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Waking state
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage 1 sleep (alpha-theta transition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage 2 sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rare stimuli
Number of subjects: 0
Study: 8810684

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) 3mg/kg per day
Number of subjects: 340

Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA)
Number of subjects: 340
Study: 1426499

Group type: EXPERIMENTAL
Intervention: Progesterone pessaries 100 mg b.d. from 48 hours prior to embryo transfer and continued throughout the luteal phase
Number of subjects: 245

Group type: COMPARATOR
Intervention: No luteal support
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Progesterone pessaries
Number of subjects: 245
Study: 3900811

Group type: EXPERIMENTAL
Intervention: Sintropium bromide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rociverine
Number of subjects: 30
Study: 30504510

Group type: EXPERIMENTAL
Intervention: DMARD tapering by 50% (arm 2)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Stopping DMARD after tapering (arm 3)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Full-dose DMARD treatment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Tapering and stopping DMARD in low-risk relapse group
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Average reduction of DMARD costs per patient
Number of subjects: 146
Study: 30359537

Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (NaNO3)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 17
Study: 27259714

Group type: EXPERIMENTAL
Intervention: MM-302 plus trastuzumab
Number of subjects: 250

Group type: COMPARATOR
Intervention: Chemotherapy of physician's choice plus trastuzumab (gemcitabine, capecitabine, or vinorelbine)
Number of subjects: 250
Study: 25249361

Group type: EXPERIMENTAL
Intervention: Exercise therapy for 12 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo ultrasound treatment
Number of subjects: 209
Study: 22512435

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (1000 mg testosterone undecanoate intramuscular injections at 0, 6, and 12 weeks)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 20131268

Group type: EXPERIMENTAL
Intervention: Corticosteroids alone
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cyclophosphamide pulses
Number of subjects: 124

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 124

Group type: COMPARATOR
Intervention: Deaths
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Disease-free survival
Number of subjects: 124
Study: 18045765

Group type: COMPARATOR
Intervention: GI, unfilled teeth (control)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GII, Endofill+gutta‐percha
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GIII, Sealer 26+gutta‐percha
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GIV, AH Plus+gutta‐percha
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GV, Epiphany+gutta‐percha
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: GVI, Epiphany+Resilon
Number of subjects: 72
Study: 15949795

Group type: EXPERIMENTAL
Intervention: Topical 0.1% diclofenac
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Diclofenac withdrawal in group A
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo in group B
Number of subjects: 32
Study: 12385927

Group type: EXPERIMENTAL
Intervention: Prophylactic alpha-blockers
Number of subjects: 234

Group type: COMPARATOR
Intervention: Therapeutic alpha-blockers
Number of subjects: 234
Study: 10084524

Group type: EXPERIMENTAL
Intervention: Accident victims
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 210
Study: 7718371

Group type: EXPERIMENTAL
Intervention: Dobutamine (4.4 micrograms kg‐1 min‐1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 1801386

Group type: EXPERIMENTAL
Intervention: Otovent treatment for two weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (observation)
Number of subjects: 100
Study: 7230728

Group type: EXPERIMENTAL
Intervention: Aspirin treatment (1.5 g/day)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Phenprocoumon treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All treatment groups after one year
Number of subjects: 3
Study: 30411377

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: Rivaroxaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dabigatran
Number of subjects: 100
Study: 28422459

Group type: EXPERIMENTAL
Intervention: Philips Sonicare DiamondClean power toothbrush
Number of subjects: 144

Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 144
Study: 26446485

Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D (25(OH)D) levels
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Total fat mass index (FMI)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Central fat mass index (android FMI)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Peripheral fat mass index (gynoid FMI)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Appendicular fat mass index (appendicular FMI)
Number of subjects: 336